'Cancer Drug Market Will Reach $75 Billion in 2012' visiongain Report Predicts

01-Mar-2012 - United Kingdom

A new report by visiongain predicts that the world market for cancer-treating drugs will reach $75 billion for 2012. That revenue forecast appears in Leading Anti-cancer Drugs and Associated Market 2012-2022, published in February 2012.

The new study predicts that overall revenues for anti-cancer treatments will increase strongly from 2012 to 2022. Individual drugs will benefit too. Roche will continue to be the leading company in the cancer-treating drugs market throughout the study's forecast period. Through emerging technologies and increasing demand in developed and developing countries, the future of cancer treatments holds great promise. That revenue growth will be mainly owing to the worldwide increase in cancer incidence and prevalence. New opportunities for cancer treatment exist, with high sales likely from many drugs - small-molecule products and biological agents (biologicals) - to 2022. Also, R&D pipelines in oncology are strong, including those for monoclonal antibodies (MAbs).

The visiongain pharmaceutical industry analyst said, "Although oncology is one of the most researched areas of medicine, there remain un-met and under-met treatment needs. There is a need for well targeted therapies with better safety and efficacy. It is crucial that anti-cancer drugs have minimal side effects, so that the quality of patients' lives can be enhanced. Pharma companies will further explore this field, making therapeutic progress this decade. In particular, companion diagnostic tests with drugs will help in cancer treatment, giving more-personalised, better-targeted medicine."

Visiongain's report provides revenue forecasts to 2022 at world market, submarket, product and national level. It forecasts world sales for the following submarkets:

  • Traditional antineoplastic agents
  • Novel antineoplastic agents
  • Hormone therapies
  • Immunotherapies
  • Other agents.

That investigation forecasts sales of 25 leading drugs in the anti-cancer treatment market, including Avastin, Rituxan, Herceptin and Glivec/Gleevec. The study also assesses eight recently approved drugs. Research, data and analyses cover activities of Roche, Novartis, AstraZeneca, Eli Lilly, Celgene and other pharmaceutical companies.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous